MG
SUPN icon

Mather Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Mather Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.12K Hold
110
– – ﹤0.01% 1617
2026
Q1 		$5.69K Buy
+110
New +$5.6K ﹤0.01% 1554
2025
Q4 		– Sell
-270
Closed -$12.9K – 1534
2025
Q3 		$12.9K Buy
+270
New +$10.9K ﹤0.01% 1214
2025
Q2 		– Sell
-270
Closed -$8.84K – 1596
2025
Q1 		$8.84K Buy
270
+160
+145% +$5.67K ﹤0.01% 1285
2024
Q4 		$3.98K Hold
110
– – ﹤0.01% 1416
2024
Q3 		$3.43K Sell
110
-140
-56% -$4.37K ﹤0.01% 1368
2024
Q2 		$8.53K Hold
250
– – ﹤0.01% 1493
2024
Q1 		$7.24K Buy
+250
New +$7.44K ﹤0.01% 1278

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Mather Group's SUPN Position: Q2 2026 in Review

Mather Group held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 110 shares worth $5.12K. The position accounts for ﹤0.01% of the portfolio, ranked #1617.

Mather Group first reported a position in SUPN in Q1 2024 and has held it in 8 quarters since. The position peaked at $12.9K in Q3 2025. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Mather Group held 110 shares of Supernus Pharmaceuticals worth $5.12K as of Q2 2026.
  • Mather Group left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1617 holding.
  • Mather Group first reported a position in Supernus Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • Mather Group's Supernus Pharmaceuticals position peaked at $12.9K in Q3 2025.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.